Cover Image
市場調查報告書

抗血栓劑:全球產業和市場展望

Antithrombotic Drugs: World Industry and Market Prospects 2015-2025

出版商 Visiongain Ltd 商品編碼 262260
出版日期 內容資訊 英文 188 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗血栓劑:全球產業和市場展望 Antithrombotic Drugs: World Industry and Market Prospects 2015-2025
出版日期: 2015年03月19日 內容資訊: 英文 188 Pages
簡介

抗血栓劑主要是抗血小板藥,抗凝血劑及纖維素溶解藥等,2012年主導的治療領域為抗血小板藥。今後由於患者的增加,在推動抗血栓劑市場成長的同時,與學名藥產品的激烈競爭則將成為阻礙市場成長的威脅。預測在2014年以後,抗凝血劑將主導該市場。

本報告囊括全球抗血栓劑市場,提供血液凝固的機制及疾病概要,包含抗血小板藥和抗凝血劑等市場的市場趨勢,市場發展促進·阻礙因素調查分析,彙整市場上主要產品及研究開發平台的產品,2015年2025年的市場預測及主要國家市場預測,再整理主要企業簡介等資料,為您概述為以下內容。

第1章 報告概要

第2章 血液凝固:機制,疾病及目前治療方法

  • 對瘀血和凝血的認識
  • 何謂血栓症
  • 血栓症的併發症
  • 透過抗血栓劑的治療

第3章 抗血栓劑:全球市場

  • 全球抗血栓劑市場,2013年·2014年
  • 全面的銷售額預測,2015-2025年
  • 抗血栓劑影響市場的發展促進·阻礙因素
    • 患者人口的增加促進市場成長
    • 跟非專利產品的激烈競爭阻礙市場成長的威脅
  • 各治療領域抗血栓劑市場:銷售額·市場佔有率預測
  • 各治療領域抗血栓劑全球市場的被未來:群組化做了的銷售額預測
  • 抗凝血劑:2014年以後主導市場
  • 抗凝血劑:2014年第2藥效分類
  • 今後纖維素溶解藥也將持續成為抗血栓劑市場不可或缺的存在

第4章 市場上主要產品

  • Plavix和Lovenox在與非專利產品的競爭中依然是2012年及2013年的市場領導
  • 主導市場的抗血栓劑:銷售額·市場佔有率比較
  • 迎向2025預測將達到最高成長率的藥品為何?
  • Plavix面臨與14非專利產品的競爭,未來展望為何?
  • Lovenox:在EU預測將與生物仿製藥競爭
  • Xarelto2014年的主導抗凝血劑
  • 主導Xa因子直接抑制劑市場
  • 2014年也持續成長的Pradaxa
  • Activase主導競爭較少的纖維素溶解藥市場
  • Effient與Brilinta競爭,Plavix與非專利產品競爭
  • Aspirin Cardio:盈利最高的阿斯匹靈
  • Angiomax直接奪取Pradaxa凝血酶抑制劑市場佔有率
  • Pletal與非專利產品的競爭及歐洲面臨使用法規
  • 美國將在比預計更早的階段便面臨與非專利產品的競爭
  • Sandoz的Enoxaparin Sodium:銷售額預測
  • Fragmin面臨從非專利產品到與Lovenox的戰鬥
  • Brilinta:面臨調查
  • Eliquis:太晚加入市場是否影響調查
  • Arixtra:Aspen由GSK取得國際專利
  • 新核准藥
    • Zontivity:最新認證核可藥
    • Lixiana/Savaysa:往其他地區市場擴大

第5章 主要國家市場

  • 2013年,2014年抗血栓劑銷售額的前幾名國家
  • 抗血栓劑的主要國家:銷售額與市場佔有率比較
  • 2025年前最急速成長的國家
  • 美國:主導2014-2025年的抗血栓劑市場
  • 歐盟5國:是否會變更生物仿製藥的認證指南
  • 日本:人口的高齡化將刺激2015-2025年抗血栓劑的需求
  • 中國抗血栓劑市場獲得市場佔有率
  • 巴西抗血栓劑市場:隨著全民醫保的擴大而強勢成長
  • 印度抗血栓劑市場受到政府醫療支出的限制
  • 俄羅斯抗血栓劑市場:醫療相關資金的不足有礙成長擴大

第6章 抗血栓劑開發平台

  • 抗血栓劑的研究開發平台:概要
  • 抗血小板藥碾子究開發平台
  • 抗凝血劑的研究開發平台
  • 纖維素溶解藥的研究開發平台
  • 其他抗血栓劑的研究開發平台

第7章 抗血栓劑市場上主要企業

  • 2014年的主要抗血栓劑廠商
  • Sanofi目前雖領導市場,但其地位是否將受到威脅?
  • Boehringer Ingelheim獲得市場佔有率
  • Bayer銷售2種抗血栓劑
  • Johnson & Johnson可能可憑有限的產品系列取得成功
  • Genentech保持市場佔有率
  • Medicines Company因為發表新藥而強化了地位
  • Eli Lilly:市場上地位由Effient的成敗決定
  • 大塚製藥:有限的抗血栓劑組合
  • Pfizer:慢慢擴大佔有率
  • Bristol-Myers Squibb在2013年大幅失去市場佔有率

第8章 抗血栓劑市場定性分析

  • 2015年的抗血栓劑市場優勢和弱點
  • 市場所面臨的機會及威脅
  • 影響抗血栓劑市場的社會,技術性,經濟,及政治要素

第9章 調查採訪

  • 採訪:Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc.
  • 採訪:Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil

第10章 調查所得的結論

  • 全球抗血栓劑市場
  • 主要國家市場
  • 產業上趨勢

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0037

Treating thrombosis - new analysis showing trends, R&D and revenue forecasts

See the future of antithrombotic medicines. For those treatments you can now get new sales predictions, also exploring research and development. Discover business potentials. And assess results, trends, technologies, therapies and opportunities.

Visiongain's updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating thrombotic disorders, finding commercial prospects to benefit your research, analyses and influence.

Please read on to explore those drug sales and find what that industry could earn in future. Forecasts to 2025 and other analyses explain and predict the antithrombotics market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

That study also shows 84 tables, 69 charts and two interviews with authorities in that field.

There you assess the future of treatments to prevent blood clotting and dissolve blood clots. And the following sections explain what our new investigation gives.

Forecasting of that world market and its segments - what does the future hold?

What're the secrets of that industry's progress? Discover in our report overall world revenue prediction to 2025 for antithrombotic medicines, with discussions.

Also find individual revenue forecasts to 2025 for eight therapeutic submarkets at world level:

  • Anticoagulants
  • Antiplatelet agents
  • Fibrinolytic treatments.

And you get forecasts for these anticoagulant drug classes:

  • Direct factor Xa inhibitors
  • Heparins
  • Direct thrombin inhibitors
  • Vitamin K antagonists
  • Other therapeutics (grouped forecast).

There assess outlooks for sales expansion, hearing where you could profit. You investigate competition and rising sales. And you examine the clinical and commercial possibilities.

And also find top medicines' potentials.

Predictions of leading products' sales

How will individual drugs perform to 2025 at world level? Our study forecasts revenues of 14 brands. Assess products, including these:

  • Plavix
  • Lovenox
  • Xarelto
  • Pradaxa
  • Activase
  • Effient
  • Aspirin Cardio
  • Pletal.

2

There you find drugs and years with highest predicted sales. You also examine competitors. So discover what's happening, understanding challenges, trends, competition and opportunities.

That work also shows geographical revenue predictions.

National markets - what outlooks for revenues?

In developed and developing countries, many opportunities for producers and sellers of antithrombotic medicines will occur from 2015 to 2025. See where, how and what's possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy and Spain (EU5)
  • BRIC nations - Brazil, Russia, India and China.

There you explore progress, needs and opportunities. What events change that market? Our work shows you, discussing trends and demands.

3

Events affecting developers, producers and sellers of those cardiovascular medicines

That report also explains issues, forces and events affecting the antithrombotics industry and market from 2015, including these:

  • Progress and outlooks for preventing and treating thrombosis, pulmonary embolism, stroke, acute coronary syndrome (ACS) and related cardiovascular disorders
  • Expanding patient populations stimulating demand for those blood regulating medicines
  • Competition from generics and biosimilars, including discussion of regulatory guidelines for biosimilar low-molecular-weight heparin (LMWH).

And these issues, among others:

  • Governmental healthcare spending and effects on that market's performance
  • R&D in antiplatelet agents, anticoagulants, heparins, vitamin K antagonists, direct thrombin inhibitors, direct factor Xa agents, fibrinolytics and other antithrombotics
  • Development of antidotes for anticoagulation drugs, and the commercial effects.

There you investigate what stimulates and restrains that industry and affects its results.

Analysis of companies and potential for rising sales - what revenues possible?

What happens next? Our study predicts that world market will rise to $22.4bn in 2019, with high revenues from 2015 to 2025.

You also see what organisations hold most potential:

  • Sanofi
  • Boehringer Ingelheim
  • Bayer
  • Johnson & Johnson
  • Genentech.

And also these firms, among others:

  • The Medicines Company
  • Eli Lilly
  • Otsuka
  • Pfizer
  • Bristol-Myers Squibb.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from that applied haematology.

4

Ways Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 helps

In particular, our new investigation gives you this knowledge:

  • Antithrombotic revenues to 2025 at overall world level, and also for 8 submarkets and 14 products - assess outlooks for production, marketing and sales
  • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors, rising companies and new entrants - explore portfolios, results, strategies, R&D and outlooks for success
  • Review of R&D by therapy group - investigate progress in research and development, finding technological and medical potentials
  • Interviews with other authorities - discover what experts in that field think, say and do, helping you stay ahead
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.

Information found nowhere else, helping your searches, analyses and plans

Our study gives independent analysis. There you get competitive intelligence found only in our work, finding where progress and money lie. You see what's possible from 2015.

With that data you're less likely to fall behind in knowledge or miss opportunity. And find in our report how you could save time and effort, also helping your planning, decisions, authority and competing.

5

Our new investigation is for everyone analysing medications for thrombosis treatment and prevention. There you discover trends, discussions and sales predictions. Avoid missing out in commercial knowledge.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Antithrombotic Drugs
  • 1.2 Why Should You Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain
  • 1.10 Glossary of Abbreviations

2. Blood Clotting: Mechanisms, Disorders and Current Treatments

  • 2.1 Understanding Haemostasis and Coagulation
  • 2.2 What is Thrombosis
  • 2.3 Complications of Thrombosis
    • 2.3.1 Pulmonary Embolism: A Thrombus Blocking Blood Supply to the Lungs
    • 2.3.2 Stroke Results From Blockage of Blood Flow to the Brain
    • 2.3.3 Acute Coronary Syndrome (ACS): Blockage of Blood Supply to the Heart
  • 2.4 Antithrombotic Drug Treatment

3. Antithrombotic Drugs: World Market 2015-2025

  • 3.1 The World Antithrombotic Drug Market in 2013 and 2014
  • 3.2 The World Antithrombotic Drug Market: Overarching Revenue Forecast 2014-2025
  • 3.3 Driving and Restraining Forces Affecting the Antithrombotic Drugs Market
    • 3.3.1 An Increasing Patient Population Drives Market Growth
    • 3.3.2 Intense Competition from Generics Threatens to Restrain the Market
  • 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue and Market Share Predictions, 2019 and 2025
  • 3.5 The Future of the World Market for Antithrombotic Drugs by Therapeutic Class: Grouped Revenue Forecasts, 2014-2025
  • 3.6 Anticoagulant Drugs: Leading the Market from 2014 Onwards
    • 3.6.1 Direct Factor Xa Inhibitors: A Novel Therapeutic Class With Great Potential
    • 3.6.2 Heparins: Second-Leading Anticoagulant Class in 2013
    • 3.6.3 Direct Thrombin Inhibitors Achieved High Growth in 2013 and 2014
    • 3.6.4 Vitamin K Antagonists Have Led the Anticoagulant Drug Market for 60 Years
  • 3.7 Antiplatelet Drugs Were the Second-Leading Therapeutic Class in 2014
  • 3.8 Fibrinolytics Will Continue to be a Staple of the Antithrombotic Drug Market

4. Leading Products in the Market: Prospects, 2015-2025

  • 4.1 Plavix and Lovenox Remain the Market Leaders in 2012 and 2013, Despite Generic Competition
  • 4.2 The Leading Antithrombotic Drugs: Comparison of Revenue and Market Share, 2019 and 2025
  • 4.3 Which Medicines Will Achieve the Highest Rate of Growth to 2025?
  • 4.4 Plavix Faces Competition from Generics, So What Does the Future Hold?
    • 4.4.1 Branded Competition for Plavix?
  • 4.5 Lovenox: Biosimilar Competition in the EU is Expected
  • 4.6 Xarelto: Leading Antithrombotic of 2014
  • 4.7 Pradaxa's Continued Growth in 2014
  • 4.8 Activase Leads the Fibrinolytics Market, With Little Competition
  • 4.9 Effient Competes with Brilinta/Brilique as well as Generic Competition for Plavix
  • 4.10 Aspirin Cardio: The Most Lucrative Version of Acetylsalicylic Acid
  • 4.11 Angiomax/Angiox is Losing Share of the Direct Thrombin Inhibitors Market to Pradaxa
  • 4.12 Pletal Faces Generic Competition and Restrictions on Use in Europe
  • 4.13 Aggrenox/Asasantin to Face Generic Competition Earlier Than Expected in the US
  • 4.14 Sandoz's Enoxaparin Sodium: Revenue Forecast 2014-2025
  • 4.15 Fragmin Faces Rivalry from Generic Competition to Lovenox
  • 4.16 Brilinta/Brilique: Investigation Closed in 2014
  • 4.17 Eliquis: Will Late Entry to the Market Affect Uptake?
  • 4.18 Arixtra: Aspen Pharmacare Has Acquired Worldwide Rights from GSK
  • 4.19 New Approvals in the Antithrombotic Drugs Market, 2014
    • 4.19.1 Zontivity: The Newest Approval in Antithrombotics
    • 4.19.2 Lixiana/Savaysa: Expansion into Other Regional Markets

5. Leading National Markets, 2014-2025

  • 5.1 Which Were the Leading National Markets for Sales of Antithrombotic Drugs in 2013 and 2014?
  • 5.2 The Leading National Markets for Antithrombotic Drugs: Comparison of Revenues and Market Shares, 2019 and 2025
  • 5.3 Which National Markets Will Grow Fastest to 2025?
  • 5.4 The US: Dominating the Antithrombotic Drug Market Through 2014-2025
  • 5.5 The EU5: Are the Guidelines for Approval of Biosimilar LMWHs Set to Change?
    • 5.5.1 Germany Leads the EU5
    • 5.5.2 France: Healthcare System Reform Will Inhibit Sales Growth?
    • 5.5.3 UK: Pharmaceutical Price Regulation Scheme
    • 5.5.4 Italy's Healthcare System - Advantages Conducive to Business
    • 5.5.5 Spain: Reductions in Governmental Healthcare Spending Will Restrict Growth
  • 5.6 Japan: The Aging Population Will Stimulate Demand for Antithrombotic Drugs from 2015-2025
  • 5.7 Chinese Antithrombotic Drug Market Will Capture Market Share
  • 5.8 Brazilian Antithrombotic Drug Market 2015-2025: Strong Growth as Universal Healthcare Coverage is Expanded
  • 5.9 Indian Antithrombotic Drug Market - Limited by Governmental Healthcare Spending?
  • 5.10 Russian Antithrombotic Drug Market: Limited Healthcare Funding Will Prevent Expansive Growth

6. Antithrombotic Drug Development: R&D Pipeline

  • 6.1 The R&D Pipeline for Antithrombotic Drugs: Overview
  • 6.2 The Antiplatelet Drug R&D Pipeline in 2014
    • 6.2.1 Pozen is Seeking a Strategic Partner for its Antiplatelet Drug, PA32540
    • 6.2.2 The Medicines Company's Kangrexel (Cangrelor) Awaits Approval
  • 6.3 The R&D Pipeline for Anticoagulants, 2014
    • 6.3.1 Heparins: Little R&D Activity in 2014
      • 6.3.1.1 Will Development of Momenta's Adomiparin Continue?
      • 6.3.1.2 The Discontinuation of Semuloparin
    • 6.3.2 The Vitamin K Antagonist Pipeline: One Product in Development in 2014
    • 6.3.3 Many Development Direct Thrombin Inhibitors Have Been Discontinued
    • 6.3.4 The Direct Factor Xa Inhibitor Pipeline: Only Two Compounds Remain
    • 6.3.5 Portola Pharmaceuticals' Betrixaban
    • 6.3.6 Sanofi Has Apparently Discontinued Development of Otamixaban
  • 6.4 The Fibrinolytics R&D Pipeline, 2014
    • 6.4.1 Lundbeck's Desmoteplase: Failed to Meet Primary Endpoint in Phase III
    • 6.4.2 Bharat Biotech and ThromboGenics' THR-100
  • 6.5 The R&D Pipeline for Other Antithrombotic Drugs, 2014
    • 6.5.1 Kyowa Hakko Kirin's KW-3357: Filed in Japan, 2014
    • 6.5.2 Asahi Kasei Pharma America's ART 123
    • 6.5.3 Regado Biosciences/Tobira Therapeutics is Developing an Anticoagulation System with an Antidote
    • 6.5.4 Isis Pharmaceuticals' ISIS-FXI Rx

7. Leading Companies in the Antithrombotic Drug Market

  • 7.1 Leading Antithrombotic Drug Manufacturers in 2014
  • 7.2 Sanofi Leads the Market, but is its Position Under Threat?
  • 7.3 Boehringer Ingelheim Captures Market Share
  • 7.4 Bayer Markets Two Antithrombotic Drugs
  • 7.5 Johnson & Johnson Can Achieve Success with a Limited Product Portfolio
  • 7.6 Genentech Will Retain Market Share
  • 7.7 The Medicines Company's Position Will be Bolstered by the Launch of its New Drug
  • 7.8 Eli Lilly: Market Position is Dependent on Success of Effient
  • 7.9 Otsuka: A Limited Antithrombotic Drug Portfolio
  • 7.10 Pfizer: A Gradually Increasing Share of the Market
  • 7.11 Bristol-Myers Squibb Had a Dramatic Loss of Market Share in 2013

8. Qualitative Analysis of the Antithrombotic Drugs Market, 2015

  • 8.1 The Strengths and Weaknesses of the Antithrombotic Drug Market in 2015
    • 8.1.1 Thrombotic Disease: Management Rather Than Cure
    • 8.1.2 The Lack of Antidotes for the Novel Oral Anticoagulants Restricts the Market
  • 8.2 Opportunities and Threats Facing the Market 2015-2025
    • 8.2.1 Rising Disease Prevalence Creates Opportunities in the Market
    • 8.2.2 Further Development of Existing Drugs
    • 8.2.3 High Demand for Antidotes to the Novel Oral Anticoagulants
    • 8.2.4 The Threat of Generic Competition
    • 8.2.5 High Level of Competition is a Threat to New Entrants - What Can Developers Do?
    • 8.2.6 High Risk of Investment in New Drug Development
    • 8.2.7 Healthcare Budget Pressures Threaten Drug Launches and Prices in Europe
  • 8.3 Social, Technological, Economic and Political Factors Influencing the Antithrombotic Drug Market 2015-2025
    • 8.3.1 Social Factors: An Expanding Patient Population and Increasing Awareness
    • 8.3.2 Technological Advances Encourage the Development of Improved Treatment Options
    • 8.3.3 Economic Factors
      • 8.3.3.1 Cost Cutting in the EU and the US
      • 8.3.3.2 Free Trade within the EU Presents Challenges
    • 8.3.4 Political Factors: Will the Affordable Care Act Increase Patient Access to Antithrombotic Drugs?

9. Research Interviews

  • 9.1 Interview with Dr Sanjay Bhanot, PhD, Vice President of Clinical Development and Translational Medicine, Isis Pharmaceuticals, Inc.
    • 9.1.1 Isis Pharmaceuticals Antithrombotic Drugs Pipeline
    • 9.1.2 ISIS-FXIRx Phase II Results
    • 9.1.3 Trends in the Antithrombotic Drug Market, 2015-2025
  • 9.2 Interview with Dr Marcelo A. Lima, Research Fellow and Professor of Molecular Biology, Department of Biochemistry, Universidade Federal de São Paulo, Brazil
    • 9.2.1 Recent Research on a Novel Heparin-Like Compound Derived From Shrimp
    • 9.2.2 Heparin vs. Novel Oral Anticoagulants
    • 9.2.3 Unmet Needs in Brazil and Worldwide
    • 9.2.4 Trends in the Antithrombotic Drug Market

10. Conclusions from Our Study

  • 10.1 The World Market for Antithrombotic Drugs 2015-2025
    • 10.1.1 The Decline of Antiplatelet Drugs and the Rise of the Anticoagulants
  • 10.2 The Leading National Markets 2015-2025
  • 10.3 Trends in the Industry
    • 10.3.1 The Market Will Recover From Plavix Decline
    • 10.3.2 The Demand for Antithrombotic Drugs is Increasing Worldwide
    • 10.3.3 Many Drugs Will Face Generic Competition Over the Coming 10 Years
    • 10.3.4 High Barriers to Market Entry and a Limited Pipeline - The Implications

List of Tables

  • Table 1.1 Antithrombotic Drugs Market Forecast, 2014-2019
  • Table 1.2 Antithrombotic Drugs Market Forecast, 2019-2025
  • Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
  • Table 2.1 An Overview of Antithrombotic Drugs by Therapeutic Class, 2014
  • Table 3.1 The Antithrombotic Drug Market by Therapeutic Class: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 3.2 Overall World Market for Antithrombotic Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.3 The Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 3.4 The Antithrombotic Drug Market by Therapeutic Class: Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
  • Table 3.5 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
  • Table 3.6 Direct Factor Xa Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.7 Heparins: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.8 Direct Thrombin Inhibitors: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.9 The Warfarin Market: Companies and Year of Introduction
  • Table 3.10 Vitamin K Antagonists: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.11 Antiplatelet Drugs: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 3.12 Fibrinolytics: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.1 Leading Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 4.2 Leading Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 4.3 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Table 4.4 Plavix: Key Facts, 2014
  • Table 4.5 Selected Generic Competitors Approved by the FDA, 2014
  • Table 4.6 Plavix: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.7 Lovenox: Key Facts, 2014
  • Table 4.8 Lovenox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.9 Xarelto: Key Facts, 2014
  • Table 4.10 Xarelto: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.11 Pradaxa: Key Facts, 2014
  • Table 4.12 Pradaxa: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.13 Activase: Key Facts, 2014
  • Table 4.14 Activase: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.15 Effient: Key Facts, 2014
  • Table 4.16 Effient: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.17 Aspirin Cardio: Key Facts, 2014
  • Table 4.18 Aspirin Cardio: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.19 Angiomax/Angiox: Key Facts, 2014
  • Table 4.20 Angiomax/Angiox: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.21 Pletal: Key Facts, 2014
  • Table 4.22 Pletal: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.23 Aggrenox/Asasantin: Key Facts, 2014
  • Table 4.24 Aggrenox/Asasantin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.25 Sandoz's Enoxaparin Sodium: Key Facts, 2014
  • Table 4.26 Sandoz's Enoxaparin Sodium: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.27 Fragmin: Key Facts, 2014
  • Table 4.28 Fragmin: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.29 Brilinta: Key Facts, 2014
  • Table 4.30 Brilinta: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.31 Eliquis: Key Facts, 2014
  • Table 4.32 Eliquis: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 4.33 Arixtra: Key Facts, 2014
  • Table 4.34 Zontivity: Key Facts, 2014
  • Table 4.35 Lixiana/Savaysa: Key Facts, 2014
  • Table 5.1 Leading National Markets for Antithrombotic Drugs: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 5.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m) and Market Shares (%), 2019 and 2025
  • Table 5.3 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Table 5.4 The US Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.5 The EU5 Market for Antithrombotic Drugs: National Revenue ($m), AGR (%) and CAGR (%) Forecasts, 2014-2025
  • Table 5.6 The German Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.7 The French Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.8 The UK Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.9 The Italian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.10 The Spanish Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.11 The Japanese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.12 The Chinese Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.13 The Brazilian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.14 The Indian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 5.15 The Russian Antithrombotic Drug Market: Revenue ($m), AGR (%) and CAGR (%) Forecast, 2014-2025
  • Table 6.1 Selected Candidates in the Antiplatelet Drug R&D Pipeline, 2014
  • Table 6.2 Selected Candidates in the Heparins Pipeline, 2014
  • Table 6.3 Selected Candidates in the Vitamin K Antagonist Pipeline, 2014
  • Table 6.4 Candidates in the Direct Thrombin Inhibitors Pipeline, 2014
  • Table 6.5 The Direct Factor Xa Inhibitor Pipeline, 2014
  • Table 6.6 The Fibrinolytics R&D Pipeline, 2014
  • Table 6.7 Other Antithrombotic Drugs in Development, 2014
  • Table 7.1 The Top 10 Companies: Revenues ($m) and Market Shares (%), 2013 and 2014
  • Table 7.2 Sanofi: Antithrombotic Drug Portfolio, 2014
  • Table 7.3 Boehringer Ingelheim: Antithrombotic Drug Portfolio, 2014
  • Table 7.4 Bayer: Antithrombotic Drug Portfolio, 2014
  • Table 7.5 Johnson & Johnson: Antithrombotic Drug Portfolio, 2014
  • Table 7.6 Genentech: Antithrombotic Drug Portfolio, 2014
  • Table 7.7 The Medicines Company: Antithrombotic Drug Portfolio, 2014
  • Table 7.8 Eli Lilly: Antithrombotic Drug Portfolio, 2014
  • Table 7.9 Otsuka: Antithrombotic Drug Portfolio, 2014
  • Table 7.10 Pfizer: Antithrombotic Drug Portfolio, 2014
  • Table 7.11 Bristol-Myers Squibb: Antithrombotic Drug Portfolio, 2014
  • Table 8.1 Strengths and Weaknesses of the Antithrombotic Drug Market, 2015
  • Table 8.2 Opportunities and Threats Facing the Antithrombotic Drug Market, 2015-2025
  • Table 8.3 Social, Technological, Economic and Political Forces Influencing the Antithrombotic Drug Market (STEP Analysis), 2015-2025

List of Figures

  • Figure 2.1 Diagram Depicting the Coagulation Cascade
  • Figure 3.1 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2013
  • Figure 3.2 The Antithrombotic Drug Market by Therapeutic Class: Market Share (%), 2014
  • Figure 3.3 The Global Market for Antithrombotic Drugs: Revenue Forecast ($m),
  • 2014-2025
  • Figure 3.4 The Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 3.5 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2019
  • Figure 3.6 The Antithrombotic Drug Market by Therapeutic Class: Market Shares (%), 2025
  • Figure 3.7 The Antithrombotic Drug Market by Therapeutic Class: Revenue Forecasts ($m), 2014-2025
  • Figure 3.8 Anticoagulant Drugs: Grouped Revenue Forecasts ($m) by Subclass, 2014-2025
  • Figure 3.9 Direct Factor Xa Inhibitors: Revenue Forecast ($m), 2014-2025
  • Figure 3.10 Direct Factor Xa Inhibitors Market: Drivers and Restraints, 2015-2025
  • Figure 3.11 Heparins: Revenue Forecast ($m), 2014-2025
  • Figure 3.12 The Heparins Market: Drivers and Restraints, 2015-2025
  • Figure 3.13 Direct Thrombin Inhibitors: Revenue Forecast ($m), 2014-2025
  • Figure 3.14 The Direct Thrombin Inhibitors Market: Drivers and Restraints, 2015-2025
  • Figure 3.15 Vitamin K Antagonists: Revenue Forecast ($m), 2014-2025
  • Figure 3.16 The Vitamin K Antagonist Market: Drivers and Restraints, 2015-2025
  • Figure 3.17 Antiplatelet Drugs: Revenue Forecast ($m), 2014-2025
  • Figure 3.18 The Antiplatelet Drug Market: Drivers and Restraints, 2015-2025
  • Figure 3.19 Fibrinolytics: Revenue Forecast ($m), 2014-2025
  • Figure 3.20 The Fibrinolytics Market: Drivers and Restraints, 2015-2025
  • Figure 4.1 The Leading Antithrombotic Drugs: Market Shares (%), 2013
  • Figure 4.2 The Leading Antithrombotic Drugs: Market Shares (%), 2014
  • Figure 4.3 The Leading Antithrombotic Drugs: Market Shares (%), 2019
  • Figure 4.4 The Leading Antithrombotic Drugs: Market Shares (%), 2025
  • Figure 4.5 Leading Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 4.6 Plavix: Revenue Forecast ($m), 2014-2025
  • Figure 4.7 Lovenox: Revenue Forecast ($m), 2014-2025
  • Figure 4.8 Xarelto: Revenue Forecast ($m), 2014-2025
  • Figure 4.9 Pradaxa: Revenue Forecast ($m), 2014-2025
  • Figure 4.10 Activase: Revenue Forecast ($m), 2014-2025
  • Figure 4.11 Effient: Revenue Forecast ($m), 2014-2025
  • Figure 4.12 Aspirin Cardio: Revenue Forecast ($m), 2014-2025
  • Figure 4.13 Angiomax/Angiox: Revenue Forecast ($m), 2014-2025
  • Figure 4.14 Pletal: Revenue Forecast ($m), 2014-2025
  • Figure 4.15 Aggrenox/Asasantin: Revenue Forecast ($m), 2014-2025
  • Figure 4.16 Sandoz's Enoxaparin Sodium: Revenue Forecast ($m), 2014-2025
  • Figure 4.17 Fragmin: Revenue Forecast ($m), 2014-2025
  • Figure 4.18 Brilinta: Revenue Forecast ($m), 2014-2025
  • Figure 4.19 Eliquis: Revenue Forecast ($m), 2014-2025
  • Figure 5.1 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2013
  • Figure 5.2 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2014
  • Figure 5.3 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2019
  • Figure 5.4 The Antithrombotic Drug Market by Leading Country: Market Shares (%), 2025
  • Figure 5.5 Leading National Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 5.6 The US Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.7 The US Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.8 EU5 Markets for Antithrombotic Drugs: Revenue Forecasts ($m), 2014-2025
  • Figure 5.9 EU5 Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.10 The German Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.11 The French Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.12 The UK Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.13 The Italian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.14 The Spanish Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.15 The Japanese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.16 The Japanese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.17 The Chinese Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.18 The Chinese Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.19 The Brazilian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.20 The Brazilian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.21 The Indian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.22 The Indian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 5.23 The Russian Antithrombotic Drug Market: Revenue Forecast ($m), 2014-2025
  • Figure 5.24 The Russian Antithrombotic Drug Market: Drivers and Restraints, 2015-2025
  • Figure 6.1 An Overview of the R&D Pipeline for Antithrombotic Drugs, 2014
  • Figure 7.1 The Top 10 Companies: Market Shares (%), 2013
  • Figure 7.2 The Top 10 Companies: Market Shares (%), 2014
  • Figure 10.1 The Global Antithrombotic Drug Market by Therapeutic Class: Comparison of Revenues ($m), 2013-2025
  • Figure 10.2 Leading National Markets for Antithrombotic Drugs: Comparison of Revenues ($m), 2014, 2019 and 2025

Companies Listed

  • Abbott Laboratories
  • Ablynx
  • Aché
  • Accord Healthcare
  • Actavis Totowa
  • AdvanceCor GmbH
  • Alchemia
  • Amneal Pharms
  • Amphastar Pharmaceuticals
  • Apotex
  • App Pharmaceuticals
  • ARCA biopharma
  • Armetheon
  • ARYx Therapeutics
  • Asahi Kasei Pharma America
  • Aspen
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Barr Laboratories (subsidiary of Barr Pharmaceuticals)
  • Barr Pharmaceuticals (now a part of Teva Pharmaceuticals)
  • Bayer
  • Baylor College of Medicine, Houston, Texas
  • Bharat Biotech
  • BioVascular
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Capital TEN II
  • Canyon Pharmaceuticals
  • Committee on Medicinal Products for Human Use (CHMP)
  • CSL Behring
  • Daiichi Sankyo
  • Dexa Medica
  • Diakron Pharmaceuticals
  • Dr. Reddy's Laboratories
  • DuPont Merck
  • Eisai
  • Eli Lilly
  • EMS
  • Endo Laboratories
  • ESP Pharma
  • Eurofarma
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fournier Pharma
  • Gate Pharmaceuticals
  • Genentech
  • German Institute for Quality and Efficiency in Health Care (IQWiG)
  • GlaxoSmithKline (GSK)
  • Grifols Therapeutics
  • Hercules Bioventures Partners
  • Hoechst Marion Roussell
  • Hospira
  • Hypermarcas
  • Indonesia University
  • Invagen Pharms
  • IPCA Labs
  • Isis Pharmaceuticals
  • Johns Hopkins Medicine
  • Johnson & Johnson (J&J)
  • Judicial Panel on Multidistrict Litigation (US)
  • Kowa
  • Kyowa Hakko Kirin
  • Lee's Pharmaceutical
  • LG Life Sciences
  • LIMES Institute
  • Lundbeck
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Mitsubishi
  • Mitsubishi Tanabe Pharma
  • Momenta Pharmaceuticals
  • Mutual Pharmaceuticals
  • Mylan Pharmaceuticals
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • Novartis
  • Nuvelo
  • Organon
  • Otsuka Pharmaceutical Company
  • Pfizer
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • Pharmacia
  • PLIVA
  • PLx Pharma
  • Portola Pharmaceuticals
  • Pozen
  • Regado Biosciences
  • Roche
  • Roxane Laboratories
  • Sandoz
  • Sanofi
  • ScieGen Pharmaceuticals
  • Sun Pharmaceuticals Indusdtries
  • Takeda
  • Taro
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • ThromboGenics
  • Tianjin Medical
  • Tobira Therapeutics
  • Torrent Pharmaceuticals
  • Tufts Medical Center
  • Unified Health System (SUS)
  • Universidade Federal de São Paulo
  • University General Hospital
  • University of Insubria (Italy)
  • Upjohn AB
  • US Department of Justice
  • USL Pharma
  • Virginia Commonwealth University
  • Wockhardt
  • World Health Organization (WHO)
  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York
  • Zydus Cadila
  • Zydus Pharmaceuticals (USA) Inc. (US Division of Cadila Healthcare)
Back to Top